SABS | SAB Biotherapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.01 - 3.32
52 Week Range	2.1600 - 9.72
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	69,444
Average Volume	73,311
Shares Outstanding	9,229,270
Market Cap	28,241,566
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-09

Valuation
Profitability
Growth
Health
P/E Ratio	-0.49
Forward P/E Ratio	N/A
EPS	-6.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	USA
Website	SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SABS's peers: ALRN, BRTX, CMMB, ABVC, EDSA, EQ, GTBP, MNKD, PCSA, PPBT, PTN, RNXT, CMRA, FRTX, THRD, CINGW, ANEB, CVKD, MNPR, UNCY, QNRX, CDIO, VRAX, PXMD, SABSW, SLRX, SYBX, TTNP, VCNX, VYNE, SNTI, IMNN, DOMH, TOVX

*Chart delayed

Analyzing fundamentals for SABS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see SABS Fundamentals page.

Watching at SABS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SABS Technicals page.